These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38501016)

  • 1. Global biomarker trends in Parkinson's disease research: A bibliometric analysis.
    Wang X; Dong T; Li X; Yu W; Jia Z; Liu Y; Yang J
    Heliyon; 2024 Mar; 10(6):e27437. PubMed ID: 38501016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bibliometric analysis of microRNAs and Parkinson's disease from 2014 to 2023.
    Chen L; Chen J; Weng W; Wu M; Zhou X; Yan P
    Front Neurol; 2024; 15():1466186. PubMed ID: 39385824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease Treatment: A Bibliometric Analysis.
    McBenedict B; Hauwanga WN; Ienaco G; Petrus D; Kazmi SS; Machado Lima J; Onabanjo BB; Felix A; Awadelseed S; Selvamani S; Cher PW; Lima Pessôa B
    Cureus; 2024 Sep; 16(9):e69613. PubMed ID: 39421091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the research of nursing in Parkinson's disease: a bibliometric and quantitative analysis.
    Liao HB; Fang YL; Chen SY; Yin YS; Li J; Zhou P; Li B; Jiang XZ; Lei YF
    Front Neurol; 2024; 15():1412158. PubMed ID: 39385816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and hotspots in non-motor symptoms of Parkinson's disease: a 10-year bibliometric analysis.
    Li X; Chen C; Pan T; Zhou X; Sun X; Zhang Z; Wu D; Chen X
    Front Aging Neurosci; 2024; 16():1335550. PubMed ID: 38298610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational molecular imaging and drug development in Parkinson's disease.
    Haider A; Elghazawy NH; Dawoud A; Gebhard C; Wichmann T; Sippl W; Hoener M; Arenas E; Liang SH
    Mol Neurodegener; 2023 Feb; 18(1):11. PubMed ID: 36759912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tandem mass tag-based quantitative proteomics analysis of plasma and plasma exosomes in Parkinson's disease].
    Zhao Y; Liu X; Zhang Y; Zhang J; Liu X; Yang G
    Se Pu; 2023 Dec; 41(12):1073-1083. PubMed ID: 38093537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.
    Andersen AD; Binzer M; Stenager E; Gramsbergen JB
    Acta Neurol Scand; 2017 Jan; 135(1):34-56. PubMed ID: 26991855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
    Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
    Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge Structure and Emerging Trends of Mild Cognitive Impairment with Dyssomnias in Recent 20 Years: A Bibliometric Analysis via CiteSpace and VOSviewer.
    Huang H; Zhuang Z; Wan Y; Shi J; Yuan X; Wang D; Chen S
    Behav Neurol; 2024; 2024():6622212. PubMed ID: 38223295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson's Disease.
    Zhao ZH; Chen ZT; Zhou RL; Zhang X; Ye QY; Wang YZ
    Front Aging Neurosci; 2018; 10():438. PubMed ID: 30692923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Mobility Group Box 1 (HMGB1) Protein in Parkinson's Disease Research: A 10-Year Bibliometric Analysis.
    Razali K; Mohamed WMY
    J Integr Neurosci; 2023 Jul; 22(4):87. PubMed ID: 37519176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on CSF Biomarkers in Parkinson's Disease.
    Kwon EH; Tennagels S; Gold R; Gerwert K; Beyer L; Tönges L
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker Research in Parkinson's Disease Using Metabolite Profiling.
    Havelund JF; Heegaard NHH; Færgeman NJK; Gramsbergen JB
    Metabolites; 2017 Aug; 7(3):. PubMed ID: 28800113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research status and hotspots in the surgical treatment of tremor in Parkinson's disease from 2002 to 2022: a bibliometric and visualization analysis.
    Zeng J; Chu H; Lu Y; Xiao X; Lu L; Li J; Lai G; Li L; Lu L; Xu N; Wang S
    Front Aging Neurosci; 2023; 15():1157443. PubMed ID: 37829141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's Disease Related Depression and Anxiety: A 22-Year Bibliometric Analysis (2000-2022).
    Zhang T; Yang R; Pan J; Huang S
    Neuropsychiatr Dis Treat; 2023; 19():1477-1489. PubMed ID: 37404573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease and the gut: Models of an emerging relationship.
    Bindas AJ; Kulkarni S; Koppes RA; Koppes AN
    Acta Biomater; 2021 Sep; 132():325-344. PubMed ID: 33857691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Trend in the Research and Development of Acupuncture Treatment on Parkinson's Disease From 2000 to 2021: A Bibliometric Analysis.
    Li X; Wei W; Wang Y; Wang Q; Liu Z
    Front Neurol; 2022; 13():906317. PubMed ID: 35873762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.